|
Media Releases |
Financial Reports |
Presen-tations |
|
07/21/2004
|
|
|
|
| Half - Year Report 2004 |
| Lonza Group's operating income decreased by 37.1% to CHF 110 million. Custom manufacturing plants remained at low levels of utilization. Start-up of the new mammalian cell fermentation plant in Portsmouth, NH (US) according to plan with first successful qualification batches and very satisfactory capacitiy utilization for 2005 and beyond. |
As announced in our full-year 2003 results, 2004 will be a rebasing year for our businesses. The combination of factors which affected the performance of Lonza in the second half of 2003 continued to have a negative impact in the first semester of 2004. In addition, the start-up cost for the Portsmouth, NH (USA) plant had to be absorbed. Compared with the first half of 2003, Group operating income decreased by 37.1% to CHF 110 million, with sales of CHF 1 088 million, representing a 6.0% decrease on the prior year, 6.6% in constant currencies. Earnings per share decreased from CHF 2.54 (before non-recurring items in 2003) to CHF 1.48 in 2004.
The full versions of the half-year report 2004 are available in the download area |
|
|
